Researchers from CeMM Research Center have developed a new method called scifi-RNA-seq that enables efficient RNA sequencing for millions of individual cells. This method marks the RNA of many cells with specific barcodes, allowing for analysis of complex tissues and organs.
Researchers found that purines can trigger a functional disturbance of BRD4 and impact chromatin accessibility. Adenine restores BRD4 functionality, suggesting its potential as a new therapeutic approach for BRD4-induced cancer types.
Researchers developed a VR platform to display huge amounts of data and analyze complex protein interactions. This enables the identification of correlations and rare genetic defects responsible for diseases.
A new study by Christoph Binder's research group identifies IgM antibodies as a key player in preventing thrombosis. Natural IgM antibodies bind to microvesicles, preventing coagulation and thrombosis, providing a novel approach to reduce the risk of this major cause of death.
Researchers found that SARS-CoV-2 mutations can evade the immune response by T-killer cells, reducing their effectiveness in detecting and eliminating viruses. The study suggests that future vaccines should target a broader range of epitopes to provide more comprehensive protection.
The study shows that the BAF complex plays a crucial role in controlling DNA accessibility and that its inhibition leads to rapid changes in chromatin structure. This has significant implications for understanding cancer development and identifying potential therapeutic targets.
Scientists discover hematoxylin compounds selectively kill mutated CALR cells, providing hope for new treatment options for primary myelofibrosis patients. The study's results show hematoxylin's ability to disrupt the interaction between mutated CALR and thrombopoietin receptor.
Scientists discovered SLC25A51 as a key regulator of NAD transport into the mitochondria, a process linked to various physiological and pathological processes. The study opens possibilities for new metabolic therapies against ageing and cancer.
A recent study reveals correlations between clusters, observing the development of new mutations and transmission chains. The research provides important insights for pandemic control and may help assess whether treatments influence virus mutation characteristics.
Researchers at CeMM have developed a scalable method to study hundreds of proteins in parallel, enabling the observation of changes in protein levels and localization in real-time. This approach has potential applications in discovering new drug treatments and understanding proteome dynamics.
Researchers found that mice with mild skin infections develop adaptive immunity against bacteria, granting increased resistance to severe secondary infections. This discovery suggests that the 'allergy module' has an important biological function in defending against toxin-producing pathogens.
The HCA|Organoid project will establish an open access Organoid Cell Atlas, enabling future discovery-driven and translational research on rare genetic diseases, complex multifactorial diseases, and cancer. The project will derive and comprehensively characterize human brain and colon organoids from 100 individuals each.
A new method, knowledge-primed neural networks (KPNNs), combines deep learning with biological interpretability to understand complex biological systems. KPNNs have been applied to large single-cell datasets, revealing unexpected diversity in cell-type-defining regulatory networks.
Researchers at CeMM developed a scalable strategy to discover novel molecular glue degraders, which can eliminate disease-causing proteins by targeting the cellular protein quality control system. The study identifies a set of novel compounds that induce the degradation of cyclin K, essential in many cancer types.
Researchers discovered widespread expression of immune genes in structural cells, which contribute to the response to pathogens. The study highlights that structural cells are not only essential building blocks but also play a key role in defending against infections.
Researchers discovered that the Mediator complex selectively safeguards a small set of cell-type-specific genes, which form densely connected regulatory circuits. This finding suggests that Mediator is not generally required for all gene transcription and instead plays a crucial role in directing cell-type-specific functions.
The release of 216 SARS-CoV-2 genomes from Austria provides insights into the virus's transmission cluster and genetic diversity. The data analysis reveals a highly diverse pool of circulating viruses, with some leading to bigger transmission clusters, and identifies key mutations in the viral S protein.
Researchers at CeMM have identified a new key element, TASL, responsible for sorting out pathogen challenges and modulating inflammatory responses. The discovery highlights potential new targets for treating autoimmune diseases and overreaction to infections.
Researchers developed a novel approach to decontaminate single-cell RNA seq data, allowing for accurate quantification of cell-specific drug effects in pancreatic islets. The method revealed species-specific and cell-type-specific responses to drugs, including the induction of insulin production in alpha cells.
The availability of Austrian SARS-CoV-2 genomes has shed light on the virus' evolutionary trajectory in the human population. Initial analysis revealed an average of 6 mutations differing from the Wuhan reference genome, suggesting positive selection pressure and evolution within the human population.
Researchers uncovered how approximately 80% of screened cytotoxic compounds rely on solute carriers for activity, providing insights into drug mechanisms and SLC biology. The study also highlights the need for systematic surveys of transporter-drug relationships to develop more effective precision therapies.
Chronic lymphocytic leukemia (CLL) patients respond differently to ibrutinib treatment due to individual genetic and epigenetic profiles. The study reveals a shared genetic program in CLL cells responding to ibrutinib, but with patient-specific execution, leading to varying disease progression rates.
Researchers found that type I interferon disrupts the urea cycle in liver cells, leading to altered serum metabolite concentrations and reduced liver pathology. This regulation affects antiviral immunity and reduces liver damage.
A novel mathematical framework has been developed to map out precisely how different perturbations of the interactome influence each other. The study reveals that the position of targets of a given drug on the interactome is not random but rather localized within drug modules.
A team of researchers, including CeMM PI Joanna Loizou, will study DNA-damage response systems using cutting-edge technologies. The six-year project aims to create integrated genetic and physical maps of DNA repair pathways in human cell types.
A study found a germline mutation in the CD137 gene to be associated with childhood lymphoma, highlighting its key role in immune surveillance against EBV infection. The research aims to develop targeted therapeutics to stop this disease process.
Researchers identified central UPS regulators as essential for degrader efficacy, and found modulator gene-networks that can inform patient stratification. The study provides new insights into the rational design of small-molecule degraders.
Researchers at CeMM Research Center have identified new targets for treating BAF mutant cancers by analyzing the effects of single subunit loss on chromatin accessibility and transcription. The study reveals that aberrant functions of remaining complexes may confer cancer-promoting properties, making them potentially druggable.
Researchers studied LCH lesions under the microscope to investigate diversity in full molecular detail. They identified multiple LCH cell subtypes, including actively dividing cells that give rise to other subtypes, revealing an interplay of developmental, immunological, and oncogenic mechanisms.
Researchers found an interaction between BRD4 and the enzyme MTHFD1 from folate metabolism, which links gene regulation to transcriptional control. This discovery promises new approaches in cancer combination therapy for aggressive tumors.
Chronic viral infections trigger cachexia through reorganized fat tissue and CD8 T cells, contrary to expectations.
Scientists at CeMM Research Center have developed a method to identify promising drug combinations for chronic lymphocytic leukemia. By combining epigenetic analysis and high-throughput imaging, researchers can predict which drugs are likely to work together effectively, reducing trial-and-error approaches.
Researchers have discovered molecular mechanisms that enable the transmission of a deadly facial tumor among Tasmanian devils. The study found that ERBB receptors and STAT3 proteins play a key role in the transmissibility of the disease, which has killed 90% of the wild population.
A new study reveals LZTR1 as a key regulator of RAS protein signaling, which is central to growth and oncogenesis. The findings provide a molecular explanation for various pathological conditions, including cancers and developmental disorders.
Researchers have discovered that basophils, immune cells long believed to only cause allergic reactions, are essential for proper lung development and homeostasis. They interact with other cell types to produce growth factors and cytokines, suggesting a potential target for novel immunotherapies in lung diseases.
Researchers identified epigenetic changes that accompany glioblastoma progression and predict patient survival. DNA methylation sequencing can be used to predict clinically relevant tumor properties.
A rare genetic defect in the WDR1 protein impairs the ability of lymphocytes to rearrange their actin cytoskeleton, leading to aberrant T-cell activation and B-cell development. This study expands the phenotypic spectrum of WDR1 deficiency, highlighting its impact on both innate and adaptive immunity.
Researchers at CeMM Research Center discovered a protective mechanism against atherosclerosis when targeting the molecule BAFF. The study found that blocking BAFF receptors actually increased plaque size, revealing an unexpected role for BAFF in reducing atherosclerosis risk.
A recent study published in Nature Communications reveals that the enzyme USP48 plays a crucial role in DNA repair and may hold promise as a therapeutic target for Fanconi Anemia. Inactivation of USP48 in FA-deficient cells restores nearly error-free repair of damaged DNA.
Researchers have identified SETD2 as a critical effector protein in MLL-fusion proteins, driving oncogenesis in AML. This finding paves the way for a more effective therapy using a combination of compounds.
Macrophages use a membrane protein called SLC4A7 to acidify their phagosomes, allowing them to kill bacteria. Impaired SLC4A7 leads to decreased capacity to kill bacteria and increased protons in the cytoplasm.
Scientists create cell models with specific DNA repair gene defects, allowing them to identify genomic scars associated with these defects. These scars can serve as biomarkers for molecular characterization of tumors and improve personalized cancer treatment.
A study published in PLOS Pathogens reveals the molecular binding partners of a chronic virus, providing new insights into the development of chronic viral infections and potential targets for treatment. The researchers mapped protein interactions using a novel approach, identifying essential proteins for viral survival and host defense.
A diabetes drug has been found to improve DNA repair in cells affected by Xeroderma pigmentosum, a rare genetic disease. The drug, acetohexamide, degrades the DNA repair enzyme MUTYH, triggering an NER-independent mechanism for removing UV-induced DNA damage.
A new approach, pharmacoscopy, has shown promising results in treating relapsed blood cancer. In the first clinical trial, 88.2% of patients achieved partial or complete remission with personalized therapies guided by pharmacoscopy.
A comprehensive analysis of gene variants in 23 different tissues and developmental stages of mice reveals tissue-specific differences in gene variant activity. The study found that genetic and epigenetic differences contribute to these patterns, with some genes escaping X-chromosome inactivation and exhibiting high rates of activity.
Scientists have created a library of 308 compounds to test drug combinations for new therapies. A study found a synergy between flutamide and phenprocoumon that efficiently killed prostate cancer cells, targeting the androgen receptor. The CLOUD library is ideal for discovering new applications for approved active ingredients.
Pharmacoscopy enables fast and accurate analysis of immune cell interactions, identifying previously unknown immunomodulatory effects of approved drugs. The technique has the potential to revolutionize personalized medicine by visualizing individual patient responses to various drugs.
A new study reveals that the first breath of a newborn releases crucial signals that shape the lifelong immunological milieu of lungs. This process protects against environmental triggers but increases susceptibility to bacterial infections, such as pneumococci.
Researchers found that Ewing sarcoma tumors display unique DNA methylation patterns, which influence gene activity and can lead to different outcomes. The study's results provide insights into the biology of Ewing sarcoma and may lead to personalized therapies with fewer side effects.